AKT1 and prostate cancer: For osseous metastatic castration-resistant prostate cancer cells, the use of simvastatin in combination with metformin could induce G1-phase cell cycle arrest via activation of AMPK, promote autophagy [40], and inhibit the growth of LNCaP cell through activating AMPK and AKT [41].